Blincyto FDA Approval History
FDA Approved: Yes (First approved December 3, 2014)
Brand name: Blincyto
Generic name: blinatumomab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Acute Lymphoblastic Leukemia
Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).
- Blincyto is indicated for the treatment of adult and pediatric patients with:
- CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
Development timeline for Blincyto
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.